根据名称进行药物检索

Levacet 与 Warfarin Sodium

Levacet 与 Warfarin Sodium互相作用以及同时服用的可能性。

检测结果:

Levacet <> Warfarin Sodium

现实性: 15.01.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用华法林一起与阿司匹林可能会导致你流血更容易。你可能需要调整剂量的基础上你的凝血酶原时间或国际标准化比率(印度). 叫你的医生及时如果你有任何不寻常或出血瘀伤、呕吐、血液在你的尿液或凳子、头疼、头晕、或弱点。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：阿司匹林，即使小剂量，可能会增加风险的出血患者在口服抗凝血剂通过抑制血小板聚集，延长流血的时间，以及诱导胃肠病变。镇痛剂/退热剂量的阿司匹林的风险增加的主要流血多于低剂量的阿司匹林；但是流血还发生低剂量的阿司匹林。

管理：这种结合，特别是镇痛剂/阿司匹林退热剂量，通常应该避免，除非潜在的好处超过了出血的风险。如果伴随的治疗是用于添加剂的抗凝血作用，监测过量的抗凝和公开的和隐匿性流血的建议。印度卢比应当经常检查和剂量进行相应调整时，阿司匹林是加入一种抗凝血剂方案。应认识到出血可能会出现没有印度卢比或凝血酶原时间的增加而增加。患者应立即报告任何出血的迹象到他们的医生，包括疼痛、肿、头疼、头晕、弱点、出血时间延长，从削减，阴道出血、流鼻血，止血的牙龈刷、不寻常的瘀伤、红色或棕色的尿液或红色或黑色的大便。病人也应该建议，以避免任何其他的柜台的口头或局部水杨酸产品。

来源

Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest 119(1 Suppl) (2001): 1S-2S
Barrow MV, Quick DT, Cunningham RW "Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases." Arch Intern Med 120 (1967): 620-4
Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R "Main comedications associated with major bleeding during anticoagulant therapy with coumarins." Eur J Clin Pharmacol 61 (2005): 439-44
Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A "Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients." J Intern Med 236 (1994): 299-304
Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83
Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98
Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8
Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58
Massel D, Little SH "Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: A meta-analysis." J Am Coll Cardiol 37 (2001): 569-78
Watson RM, Pierson RN "Effect of anticoagulant therapy upon aspirin-induced gastrointestinal bleeding." Circulation 24 (1961): 613-6
Chesebro JH, Fuster V, Elveback LR, et al "Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole." Am J Cardiol 51 (1983): 1537-41
Weiss HJ, Aledort LM, Kochwa S "The effect of salicylates on the hemostatic properties of platelets in man." J Clin Invest 47 (1968): 2169-80
Bates ER, Mukherjee D, Lau WC "Drug-drug interactions involving antiplatelet agents." Eur Heart J 24 (2003): 1707-9
"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals, Wilmington, DE.
Donaldson DR, Sreeharan N, Crow MJ, Rajah SM "Assessment of the interaction of warfarin with aspirin and dipyridamole." Thromb Haemost 47 (1982): 77